Clinical trial NCT05870631: Immunogenicity and Safety of DTaP or DT Vaccine in 6 Year Old Children ( DTaP/DT )
Official title: Immunogenicity and Safety of Adsorbed Diphtheria, Tetanus, Acellular Pertussis Combined Vaccine or Adsorbed Diphtheria Tetanus Combined Vaccine in 6 Years Old Children#a Randomized, Controlled Clinical Study
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Vaccine Reaction
Keywords: immunogenicity，safety，DTap，DT
Lead sponsor: Zhejiang Provincial Center for Disease Control and Prevention
Sponsor class: OTHER_GOV
Collaborators: name: China National Biotec Group Company Limited
First posted: 2023-05-23
Enrollment: 480
Sex: ALL
Minimum age (years): 72
Maximum age (years): 84
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: This study is to evaluate the immunogenicity and safety of DTaP or DT given in children aged 6 years.

Detailed description: A phase 4 trial was conducted in Zhejiang Province aimed to evaluate the immunogenicity and safety of DTaP or DT in children aged 6 years. DTaP and DT are produced by Chengdu Institute of Biological Products Co., Ltd. Participants will be recruited and randomly divided into two groups to receive DTaP or DT in 1:1 ratio. Two blood samples were taken on Day 0 (pre-vaccination) and Day 28\~42 (after-vaccination) for test antibody against pertussis, diphtheria and tetanus. Adverse events and serious adverse events were actively collected by staff within 28 days of vaccination.

Eligibility criteria: Inclusion Criteria:

* 1. Participants aged ≥ 6 on the day of enrollment; 2. Informed consent should be signed and dated by the participants; 3. The participant's legal guardian is able to attend all planned follow-up visits and comply with all study procedures; 4. The participants have received 4 doses of acellular TDap vaccine and have not received any immunization agents related to diphtheria, tetanus, and pertussis in the past 3 years; 5. The participant has no diease history of pertussis, diphtheria or tetanus; 6. ≥ 14 days interval between the last vaccination; 7. Body temperature was ≤37.3℃.

Exclusion Criteria:

* 1、Being allergic to any component of vaccines ； 2、A history of severe allergic reactions to any vaccine (for example acute allergic reaction, angioneurotic edema, dyspnea, etc）； 3、Having a history or family history of convulsions, encephalopathy, psychosis, uncontrolled epilepsy and other progressive neurological diseases; 4、Participants are suffering from immunodeficiency, receiving immunosuppressant therapy (oral steroid hormones) during treatment for malignancy, or having low immunity due to HIV, or having congenital immune disorders in close family members; 5、Injection of non-specific immunoglobulin within 1 month before enrollment; 6、Participants are suffering from acute febrile diseases and infectious diseases; 7、A history of clearly diagnosed thrombocytopenia or other clotting disorders that may contraindicate subcutaneous injection; 8、Participants with severe chronic diseases or acute episodes of chronic diseases; 9、Participants with infectious, suppurative and allergic skin diseases; 10、Other Participants whose physical conditions, as determined by the investigator, are not suitable for inclusion in clinical studies.

Primary outcomes:
measure: Seroconversion rates of the vaccination
timeFrame: 28-42 days after the dose of DTaP or DT
measure: Seropositive rates after the vaccination
timeFrame: 28-42 days after the dose of DTaP or DT
Secondary outcomes:
measure: Safety of the DTaP or DT vaccine immunization
timeFrame: 28 days after the vaccination
measure: Geometric mean antibody concentrations before the vaccination
timeFrame: before the dose of DTaP or DT
measure: Geometric mean antibody concentrations after the vaccination
timeFrame: 28-42 days after the dose of DTaP or DT
Other outcomes:
Locations:
city: Hangzhou
country: China
facility: Fuyang Center for Disease Control and Prevention
state: Zhejiang
city: Jiaxing
country: China
facility: Tongxiang Center for Disease Control and Prevention
state: Zhejiang
Study officials:
References: